Study #2023-0990
A phase 3, open-label, randomized study to compare the efficacy and safety of Luspatercept (ACE-536) vs Epoetin Alfa for the treatment of anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate-risk myelodysplastic syndrome (MDS) in erythropoietin-stimulating agent (ESA)-naive participants who are non-transfusion dependent (NTD): the "ELEMENT-MDS" trial
MD Anderson Study Status
Enrolling
Treatment Agent
Luspatercept, Epoetin Alfa
Description
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelodysplastic Syndromes
Study phase:
Phase III
Physician name:
Guillermo Garcia-Manero
Department:
Leukemia
For general questions about clinical trials:
1-833-391-3015
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.